文献速递药物不良反应与药物警戒

人工智能用于监管证据:欧洲药品管理局监管建议与公开报告的系统性文件分析

Artificial Intelligence for Regulatory Evidence: A Systematic Document Analysis of European Medicines Agency Regulatory Advice and Public Reports.
PubMed 文献 · Clin Pharmacol Ther · 2026-05-07

本研究系统分析欧洲药品管理局(EMA)公开报告与内部开发建议文件,评估人工智能(AI)在监管证据中的使用情况。筛查26480份文件,52份涉及AI使用,反映43个独特AI工具,覆盖质量、非临床、临床和药物警戒领域。AI主要用于临床申请,EMA评论涉及文档、方法学、验证和生命周期管理,AI使用仍有限但呈增长趋势。

要点

  • 筛查26480份EMA文件,仅52份涉及AI使用,反映43个独特AI工具。
  • AI工具多数部署于临床申请,输出用作终点、塑造试验方法或辅助分析。
  • EMA对AI的评论因使用背景而异,涵盖文档、方法学、验证与生命周期管理。

核心结论

  • AI在监管证据中的使用仍有限但呈增长趋势,监管先例有限,AI特异性指南制定与跨辖区协调仍在进行中。

研究设计与样本

  • 系统性文件分析,审查EMA公开报告和内部开发建议文件,共筛查26480份文件。

主要发现

  • 52份文件包含AI使用,反映43个独特AI工具,覆盖质量、非临床、临床和药物警戒领域。
  • 多数AI工具部署于临床申请,输出直接作为终点、塑造临床试验方法或用于辅助分析。
  • EMA评论因使用背景而异,涵盖文档、方法学、验证和生命周期管理方面。

局限性

  • AI领域仍新颖,监管先例有限,AI特异性指南制定与跨监管辖区协调仍在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Artificial intelligence (AI) is receiving increasing attention across the entire lifecycle of medicines, from early development to postauthorization use. While various AI tools have been developed in commercial and academic settings, the extent of their use in regulatory contexts within the European Union remains unknown. In this study, we systematically analyzed the use of AI for regulatory evidence by reviewing Public reports and internal development advice documents from the European Medicines Agency (EMA). Of 26,480 documents screened, 52 documents contained AI use, reflecting 43 unique AI tools used across quality, nonclinical, clinical, and pharmacovigilance domains. The majority of AI tools were deployed in clinical applications, and outputs were used either directly as endpoints, in shaping clinical trial methodology, or in ancillary analyses. Comments and advice from the EMA regarding AI use varied according to the context of use and covered aspects of documentation, methodology, validation, and lifecycle management. Our findings indicate that AI use in regulatory evidence is still limited but showing an increasing trend. As the field is still novel, there are limited regulatory precedents, and AI-specific guideline development and harmonization across regulatory jurisdictions are still ongoing. In this light, the quantitative characterization of AI tools and AI-related regulatory comments captured in this analysis provide concrete insights into AI use and frequent regulatory considerations, aiding in both AI tool and AI guideline development.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Nollen LM, van Westen GJP, Westman G, et al. Artificial Intelligence for Regulatory Evidence: A Systematic Document Analysis of European Medicines Agency Regulatory Advice and Public Reports. Clin Pharmacol Ther. 2026. PMID: 42095708. doi:10.1002/cpt.70300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。